BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 31

• Business

  Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results

  Cognition Therapeutics, Inc. today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2023 on Tuesday, March 26, 2024 before the market open.

  March 15, 2024

   · 

  5 min read
• Drug Development

  Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder

  Cybin Inc. today announced the initiation of a Phase 2 proof-of-concept study of CYB004, its proprietary DMT molecule in development for the treatment of GAD.

  March 15, 2024

   · 

  9 min read
• Business

  NEUPATH HEALTH REPORTS FOURTH QUARTER AND YEAR-END 2023 RESULTS

  NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced its financial and operating results for the three months and year ended December 31, 2023.

  March 15, 2024

   · 

  11 min read
• Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®

  Clene Inc. today reported the publication of “Protein Corona Composition of Gold Nanocatalysts” in the journal ACS Pharmacology & Translational Science, a journal of the American Chemical Society.

  March 15, 2024

   · 

  8 min read
• Pharm Country

  Nuvectis Pharma to Present at the 36th Annual Roth Conference

  Nuvectis Pharma, Inc. today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 36th Annual Roth Conference.

  March 15, 2024

   · 

  1 min read
• Business

  Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results

  Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today reported its fourth quarter and full-year 2023 operating and financial results and reviewed recent business highlights.

  March 15, 2024

   · 

  10 min read
• Deals

  Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares

  Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that on March 11, 2024, it received two letters from the listing qualifications department staff of The Nasdaq Stock Market.

  March 15, 2024

   · 

  5 min read
• Policy

  FDA Roundup: March 15, 2024

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

  March 15, 2024

   · 

  4 min read